SLDBSolid Biosciences Inc.

Nasdaq solidbio.com


$ 8.55 $ -0.42 (-4.68 %)    

Tuesday, 21-May-2024 15:05:56 EDT
QQQ $ 454.82 $ 1.02 (0.23 %)
DIA $ 398.57 $ -0.04 (-0.01 %)
SPY $ 530.36 $ 1.04 (0.2 %)
TLT $ 91.26 $ -0.25 (-0.28 %)
GLD $ 225.37 $ -0.67 (-0.3 %)
$ 9.12
$ 8.97
$ 8.34 x 105
$ 8.58 x 105
$ 8.35 - $ 8.97
$ 1.81 - $ 15.05
210,376
na
347.98M
$ 1.16
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 03-13-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-23-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 04-27-2022 03-31-2022 10-Q
10 03-14-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
13 05-14-2021 03-31-2021 10-Q
14 03-15-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 03-12-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-14-2019 06-30-2019 10-Q
21 05-13-2019 03-31-2019 10-Q
22 03-13-2019 12-31-2018 10-K
23 11-13-2018 09-30-2018 10-Q
24 08-10-2018 06-30-2018 10-Q
25 05-10-2018 03-31-2018 10-Q
26 03-29-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-solid-biosciences-maintains-16-price-target

HC Wainwright & Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $16 price target.

 barclays-maintains-overweight-on-solid-biosciences-lowers-price-target-to-18

Barclays analyst Gena Wang maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and lowers the price target from $21 ...

 solid-biosciences-q1-eps-064-inline

Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.64) per share which met the analyst consensus estimate. This i...

 solid-biosciences-receives-rare-pediatric-disease-designation-from-the-fda-for-duchenne-muscular-dystrophy-gene-therapy-candidate-sgt-003

Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and card...

 william-blair-initiates-coverage-on-solid-biosciences-with-outperform-rating-announces-price-target-of-40

William Blair analyst Tim Lugo initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Outperform rating and announces ...

 barclays-maintains-overweight-on-solid-biosciences-raises-price-target-to-21

Barclays analyst Gena Wang maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and raises the price target from $8 t...

 citigroup-initiates-coverage-on-solid-biosciences-with-buy-rating-announces-price-target-of-16

Citigroup analyst David Hoang initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Buy rating and announces Price Ta...

 blend-labs-reports-q4-results-joins-alta-equipment-despegarcom-and-other-big-stocks-moving-higher-on-friday

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ: BLN...

 hc-wainwright--co-reiterates-buy-on-solid-biosciences-maintains-16-price-target

HC Wainwright & Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $16 price target.

 piper-sandler-upgrades-solid-biosciences-to-overweight-raises-price-target-to-20

Piper Sandler analyst Christopher Raymond upgrades Solid Biosciences (NASDAQ:SLDB) from Neutral to Overweight and raises the...

 top-4-health-care-stocks-you-may-want-to-dump-in-february

As of Feb. 15, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION